SOBRsafe (NASDAQ: SOBR), a provider of next-generation alcohol detection technology, has announced it entered into definitive agreements for the immediate exercise of certain outstanding warrants at a reduced exercise price of $1.05 per share. The transaction is expected to generate gross proceeds of approximately $3.1 million before fees and expenses. In connection with the exercise, the company will issue new unregistered Series E and Series F warrants to purchase an aggregate of 4.7 million shares. The offering is expected to close on or about July 16, 2026, with net proceeds designated for working capital and general corporate purposes. H.C. Wainwright & Co. is serving as the exclusive placement agent.
This capital raise is significant for SOBRsafe as it strengthens the company's financial position, providing additional resources to advance its innovative alcohol detection technology. SOBRsafe's transdermal (touch-based) technology detects and reports the presence of alcohol in real time through the user's skin, eliminating the need for breath, blood, or urine samples. The company's solutions serve the behavioral health, family law, and consumer markets, offering passive and dignified screening and monitoring. The proceeds from this warrant exercise will support working capital needs and general corporate purposes, potentially accelerating product development and market expansion.
For investors, this development signals confidence in SOBRsafe's growth prospects, as warrant holders chose to exercise their warrants despite a reduced price, indicating belief in the company's future. The company's focus on real-time alcohol detection addresses a growing demand for non-invasive monitoring solutions in various sectors. With a powerful backend data platform, SOBRsafe provides comprehensive screening and monitoring capabilities. The transaction details are available in the full press release at https://nnw.fm/jzJjF. More information about SOBRsafe can be found at www.sobrsafe.com.
